Eli Lilly, Immunocore deal
Immunocore partnered with Eli Lilly to use Immunocure’s ImmTAC technology to discover and develop ImmTACs against three undisclosed jointly selected targets for cancer. ImmTACs are bispecific molecules consisting of a soluble monoclonal T cell receptor (mTCR) fused to an anti-CD3 antibody fragment that recruits T cells to the tumor.
Immunocore will receive $15 million in cash up front per target program to generate preclinical candidate packages. For each program Lilly chooses to develop further, Immunocore will receive an opt-in fee of $10 million and an option to continue co-development on a cost-sharing and profit-sharing basis. If Immunocore does not exercise the option, the company will be eligible for undisclosed milestones, plus royalties. ...